

# **13-valent Pneumococcal Conjugate Vaccine for Adults**

Nancy M. Bennett, MD, MS  
Pneumococcal Vaccines Work Group Chair  
Advisory Committee on Immunization Practices  
June 20, 2012

# Pneumococcal Vaccines Work Group

## **ACIP members**

Nancy Bennett  
Wendy Keitel  
Jeffrey Duchin  
Michael Marcy

## **Ex Officio members**

Mark Grabowsky  
Kristin Nichol  
Lucia Lee

## **CDC**

Tamara Pilishvili  
Cynthia Whitney  
Matt Moore  
Kathleen Dooling  
Tom Hennessy  
Sandra Steiner  
Gina Mootrey  
Ray Strikas  
Jorge Arana  
Maria Cano  
Erin Kennedy  
Carolyn Bridges  
Charles LeBaron

## **Liaison Representatives**

Lorry Rubin  
Rick Zimmerman  
William Schaffner  
Caroline Quach  
Daniel Musher  
Mary Glode  
Jane Zucker  
Lisa Jackson  
Monica Farley  
Kathy Neuzil  
Julie Morita  
Anthony Brenneman  
Sandra Fryhofer

# 13-valent Pneumococcal Conjugate Vaccine (PCV13) for Adults

- Licensed for use among adults  $\geq 50$  years old on 12/30/11
- FDA approved under the Accelerated Approval Pathway
- Based on non-inferior immunogenicity compared to PPSV23
- Indications
  - Prevention of pneumococcal disease (including pneumonia and invasive disease) in adults 50 years of age and older
  - Prevention of disease caused by *Streptococcus pneumoniae* serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F
- Post-approval condition of licensure: Randomized controlled trial of PCV13 against pneumococcal pneumonia among adults  $\geq 65$  years old in the Netherlands

# **Pneumococcal Vaccines Work Group: Terms of Reference**

- Review data on immunogenicity, efficacy, and cost-effectiveness of pneumococcal conjugate vaccines in adults
- Determine whether data available to date on PCV13 immunogenicity and cost-effectiveness are sufficient to determine value of immunizing adults with PCV13
- Develop a revised statement on pneumococcal immunization if determined that one including PCV13 recommendations for adults is necessary

# Summary of Feb 2012 Deliberations: PCV13 for Adults

- Reviewed and presented to ACIP evidence for PCV13 use among adults  $\geq 50$  years
- Deferred recommendation until more data available
  - Efficacy against pneumonia (CAPITA trial, results in 2013)
  - Indirect (herd) effects of PCV13 use in children

# Tentative Timeline for ACIP Meetings

ACIP Meeting	Topic	Vote?
June 2012	Vote on immunocompromised adult recommendations. Update on indirect effects from use of PCV13 in children	Yes
Oct 2012	Update on indirect effects from use of PCV13 in children	No
Feb 2013	Report on CAPITA trial results, if available. Update on indirect effects from use of PCV13 in children.	Possible
June 2013	Report on CAPITA trial results, if available. Update on indirect effects from use of PCV13 in children.	Likely

# Pneumococcal Vaccines Work Group

## Today's Presentations

1) Impact of PCV13 use in children	Dr. Matthew Moore (CDC/NCIRD)
2) PPSV23 for adults with immunocompromising conditions: background, review of data, and GRADE	Ms. Tamara Pilishvili (CDC/NCIRD)
3) PCV13 for adults with immunocompromising conditions: background, review of data, and GRADE	Dr. Kathleen Dooling (CDC/NCIRD)
4) Cost-effectiveness of PCV13 for adults with immunocompromising conditions	Dr. Charles Stoecker (CDC/NCIRD)
5) Recommendations for PCV13 use among immunocompromised adults: Vote	Ms. Tamara Pilishvili (CDC/NCIRD)